

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 18, 2023

The Board is pleased to announce that all the proposed resolutions as set out in the AGM Notice dated April 24, 2023 were duly passed by the Shareholders of the Company at the AGM held on May 18, 2023 by way of poll.

Reference is made to the circular (the “**AGM Circular**”) of Ascentage Pharma Group International (the “**Company**”) and the notice (the “**AGM Notice**”) of the annual general meeting (the “**AGM**”) of the Company both dated April 24, 2023. Terms used in this announcement shall have the same meanings as those defined in the AGM Circular and the AGM Notice unless the context requires otherwise.

POLL RESULTS OF THE AGM

As at the date of the AGM, the number of Shares in issue was 287,791,807 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions proposed at the AGM. There were no Shareholders who were entitled to attend the AGM but were required to abstain from voting in favour of any of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required to abstain from voting on any of the resolutions proposed at the AGM. No Shareholder was entitled to attend and vote only against any of the resolutions proposed at the AGM. No parties had stated their intention in the AGM Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Board is pleased to announce that all the proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders by way of poll at the AGM. The poll results of all the resolutions proposed at the AGM are as follows:

Ordinary Resolutions*		Number of votes cast (approximate percentage of total number of votes)	
		For	Against
1.	To consider and adopt the audited consolidated financial statements of the Company and the reports of the Directors and the auditor for the year ended December 31, 2022.	37,715,845 (100.00%)	0 (0.00%)
2(a).	To re-elect Dr. Yang Dajun as an executive Director.	35,793,299 (94.90%)	1,922,546 (5.10%)
2(b).	To re-elect Dr. Wang Shaomeng as a non-executive Director.	36,212,605 (96.01%)	1,503,240 (3.99%)
2(c).	To re-elect Dr. Lu Simon Dazhong as a non-executive Director.	37,484,348 (99.39%)	231,497 (0.61%)
3.	To authorize the Board to fix the Directors' remuneration.	37,715,845 (100.00%)	0 (0.00%)
4.	To re-appoint Ernst & Young as auditor of the Company, to hold office until the conclusion of the next annual general meeting of the Company, and to authorize the Board to fix their remuneration.	37,715,845 (100.00%)	0 (0.00%)
5.	To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company with an aggregate number of not exceeding 20% of the total number of shares of the Company in issue as at the date of the passing of the relevant resolution at the AGM.	34,643,828 (91.85%)	3,072,017 (8.15%)
6.	To grant a general mandate to the Directors to repurchase the Company's shares with a total number of not more than 10% of the total number of shares of the Company in issue as at the date of the passing of the relevant resolution at the AGM.	37,715,845 (100.00%)	0 (0.00%)
7.	To extend the general mandate granted to the Directors under resolution 5 by an amount representing the aggregate number of the Company's shares repurchased by the Company under resolution 6, provided that such amount shall not exceed 10% of the total number of shares of the Company in issue as at the date of the passing of the relevant resolution at the AGM.	34,643,828 (91.85%)	3,072,017 (8.15%)

* The full text of the resolutions is set out in the AGM Notice.

Tricor Investor Services Limited, the Company's Hong Kong Branch Share Registrar, acted as the scrutineer at the AGM for the purpose of vote-taking. As more than 50% of the votes were cast in favour of each of the resolutions 1 to 7, these resolutions were duly passed as ordinary resolutions at the AGM. The following Directors attended the AGM: Dr. Yang Dajun, Dr. Wang Shaomeng, Dr. Lu Simon Dazhong, Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky.

By Order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, May 18, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director; Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors; and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.